- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04121091
Pramipexole to Target "Anhedonic Depression" (PILOT-PRAXOL)
September 14, 2021 updated by: Daniel Lindqvist, Region Skane
Pramipexole Augmentation to Target Anhedonia in Depression - a Pilot Study
The heterogeneity of depression suggests that different neurocircuits and pathophysiological mechanisms are involved.
Anhedonia - the inability to experience pleasure from, or the lack of motivation to carry out, usually enjoyable activities - is an endophenotype within the depression spectrum, with a distinct pathophysiology of dopaminergic mesolimbic projections.
Anhedonia is common in depression and associated with treatment resistance.
Pramipexole, an agonist to the dopamine -receptor 3, is an established treatment of Parkinson's disease.
Based on its mechanism of action, pramipexole might be efficacious in a subtype of depression characterized by anhedonia and lack of motivation - symptoms linked to dopaminergic hypofunction.
In this proof-of-concept pilot study the investigators test the anti-anhedonic and antidepressant effects of add-on pramipexole using an "enriched population study design" including only depressed patients with significant anhedonia.
To understand the neurobiology of anhedonia in depression and to identify treatment predictors, the investigators also do assessments of anhedonia-related neurocircuitry using (f)MRI and blood biomarkers.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lund, Sweden, 22358
- Psychiatry Clinic, Lund, Region Skåne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 and ≤75.
- Diagnosis of unipolar depression; bipolar disorder in depressive phase or dysthymia.
- Symptoms of depression; Total-score ≥ 18, measured by Montgomery-Åsberg Depression Rating Scale (MADRS).
- Symptoms of anhedonia; Total-score < 27, measured by Dimensional Anhedonia Rating Scale (DARS).
- Ongoing treatment with at least one antidepressant drug ≥ 4 weeks without major changes in dosage. Patients with bipolar disorder must have a mood-stabilizing drug treatment.
- Must sign an informed consent. -
Exclusion Criteria:
- Ongoing pregnancy, breastfeeding or planning for pregnancy.
- High suicidality assessed by the researcher with medical degree.
- Ongoing substance use disorder (last 12 month).
- Diagnosis of psychosis.
- Ongoing involuntary psychiatric treatment.
- History of Impulse-control disorder or current ADHD diagnosis.
- Diagnosis of Intellectual disability, dementia, or other circumstances leading to difficulties to understand the implications of participating in the study and to give informed consent.
- Diagnosis of renal failure (eGFR < 50 ml/min/1,73 m2 ) or severe cardiovascular disease (defined as symptoms of heart failure NYHA class 2).
- Recently committed to psychotherapy (during the last 6 weeks) or planning for psychotherapy during the participation of the study.
- Ongoing ECT-treatment.
- Other diseases, disorders or medical treatments that according to the researchers might influence the results of the study or increases the risks of the study. Such as Parkinson's disorder, liver failure, cancer not in remission (for at least over a year).
- Confirmed or suspected allergy to the active substance or excipients of the drug used in this study.
- Committed to other trials
- Other reasons that according to the researcher might prevent the subject to fulfill the obligations of the study. For example insufficient drug compliance. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pramipexole
|
Add-on pramipexole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dimensional Anhedonia Rating Scale (DARS) score
Time Frame: baseline to week 10
|
Change in anhedonia symptoms (total score on the DARS).
The range is 0-68, lower score indicating more severe anhedonia.
|
baseline to week 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response/remission
Time Frame: baseline to week 10
|
Montgomery Åsberg Depression Rating Scale (MADRS) reduction 50%, MADRS ≤ 10 respectively
|
baseline to week 10
|
Montgomery Åsberg Depression Rating Scale (MADRS) score
Time Frame: baseline to week 10
|
Change in depression symptoms (total score on the MADRS)
|
baseline to week 10
|
Snaith-Hamilton Anhedonia Pleasure Scale
Time Frame: baseline to week 10
|
Change in anhedonia symptoms (total score on the Snaith-Hamilton Anhedonia Pleasure Scale)
|
baseline to week 10
|
the Motivation and Pleasure Scale
Time Frame: baseline to week 10
|
Change in motivation/anhedonia symptoms (total score on the the Motivation and Pleasure Scale)
|
baseline to week 10
|
Generalized Anxiety Disorder-7
Time Frame: baseline to week 10
|
Change in anxiety symptoms (total score on the the Generalized Anxiety Disorder-7 scale)
|
baseline to week 10
|
Insomnia Severity Index
Time Frame: baseline to week 10
|
Change in insomnia symptoms (total score on the the Insomnia Severity Index scale)
|
baseline to week 10
|
Fatigue Severity Scale
Time Frame: baseline to week 10
|
Change in fatigue symptoms (total score on the the Fatigue Severity scale)
|
baseline to week 10
|
The Apathy Evaluation Scale
Time Frame: baseline to week 10
|
Change in apathy symptoms (total score on the the The Apathy Evaluation Scale)
|
baseline to week 10
|
Change in inflammatory biomarkers
Time Frame: baseline to week 10
|
The investigators will measure blood levels of Interleukin-6, C-reactive protein, Tumor Necrosis Factor Alpha, and White Blood Cell count at baseline and at study completion.
The investigators will test if baseline levels and treatment-associated change in inflammatory markers can predict treatment response
|
baseline to week 10
|
Change in brain imaging parameters
Time Frame: baseline to week 10 (and baseline data as potential predictor)
|
Structural imaging, followed by resting-state functional imaging, diffusion tensor imaging and thereafter the monetary incentive delay task
|
baseline to week 10 (and baseline data as potential predictor)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 4, 2019
Primary Completion (Actual)
March 18, 2021
Study Completion (Actual)
March 18, 2021
Study Registration Dates
First Submitted
October 4, 2019
First Submitted That Met QC Criteria
October 8, 2019
First Posted (Actual)
October 9, 2019
Study Record Updates
Last Update Posted (Actual)
September 16, 2021
Last Update Submitted That Met QC Criteria
September 14, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Anhedonia
- Bipolar Disorder
- Dysthymic Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Dopamine Agonists
- Dopamine Agents
- Antioxidants
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pramipexole
Other Study ID Numbers
- 2019-001907-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anhedonia
-
CEN BiotechCEN Nutriment; Biovet Conseil; Amadeite SASCompletedAnhedonia in Healthy Volunteers
-
Maastricht UniversityAristotle University Of Thessaloniki; P1vital Products LTD.; Biotrial; University... and other collaboratorsCompletedDepression | Schizophrenia | Motivation | Anhedonia, Physical | Anhedonia, Social | Negative Symptoms With Primary Psychotic DisorderGermany, Greece, Netherlands, Spain
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); Duke UniversityCompletedAnhedoniaUnited States
-
University of OxfordRecruiting
-
University of ManitobaEnrolling by invitation
-
The University of Texas Health Science Center,...Emory UniversityCompleted
-
Jiangsu Province Nanjing Brain HospitalNot yet recruiting
-
University of New MexicoNational Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); Duke UniversityCompletedAnhedoniaUnited States
Clinical Trials on Pramipexole Pill
-
University of California, San DiegoNational Institute of Mental Health (NIMH); New York State Psychiatric InstituteNot yet recruitingDepression | Anxiety Disorders | Anxiety | Social DisconnectionUnited States
-
Boehringer IngelheimTerminatedTourette SyndromeUnited States, Germany
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedParkinson DiseaseFrance, Germany, Netherlands
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedParkinson Disease